准备技术是否改变了富血小板血的代谢物概况?
Bilge Başak Fidan1, Emine Koç2, Emine Çiftçi Özotuk3
1Department of Bioengineering, Graduate School of Science and Engineering, Hacettepe University, Ankara 06800, Türkiye.
Bioengineering (Basel, Switzerland)
|July 29, 2025
概括
富血小板血 (PRP) 制备方法显著改变其生化特征,影响治疗潜力. 为了获得一致的临床结果,需要标准化,针对特定适应症的PRP产品.
科学领域:
- 生物化学 生物化学
- 生物技术是生物技术.
- 再生医学是一种再生医学.
背景情况:
- 富血小板血 (PRP) 由于其再生和抗炎性质,用于肌肉骨治疗.
- 缺乏标准化的PRP制备方案导致不一致的临床结果.
研究的目的:
- 为了比较10种不同的PRP类型的代谢概况.
- 为了确定制备方法与捐赠者的变异性对PRP组成的影响.
主要方法:
- 使用Q-TOF LC-MS分析10种PRP类型的非目标代谢学.
- 从单个和多个捐赠者准备的PRP的比较.
- 多变量分析,VIP分数和路径丰富分析.
主要成果:
- PRP配方显示出与炎症,氧化还原平衡,类固醇代谢,能量和血小板激活相关的独特代谢概况.
- 单个和多个捐赠者组的高集团内部相似性.
- 制备方法是影响PRP生物化学成分的主要因素.
结论:
- 在PRP制备方案中微小的变化会导致显著的生化变化,影响治疗结果.
- 需要标准化,针对特定指示的PRP产品.
- 代谢分析对于选择最佳的PRP配方用于临床使用是有价值的.
相关概念视频
Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...


